PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

Abul Azad; Maryam Arshad; Daniele Generali; Katharina Feldinger; Merel Gijsen; Carla Strina; Mariarosa Cappelletti; Daniele Andreis; Russell Leek; Syed Haider; Pirkko-Liisa Kellokumpu-Lehtinen; Ioannis Roxanis; Adrian Llewellyn Harris; Abeer Mahmoud Shaaban; Heikki Joensuu; Anthony Kong

doi:10.1002/cac2.12632

Cancer Communications ›› 2025, Vol. 45 ›› Issue (01) : 68-73. DOI: 10.1002/cac2.12632

LETTER TO THE JOURNAL

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Abul Azad, Maryam Arshad, Daniele Generali, Katharina Feldinger, Merel Gijsen, Carla Strina, Mariarosa Cappelletti, Daniele Andreis, Russell Leek, Syed Haider, Pirkko-Liisa Kellokumpu-Lehtinen, Ioannis Roxanis, Adrian Llewellyn Harris, Abeer Mahmoud Shaaban, Heikki Joensuu, Anthony Kong. PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer. Cancer Communications, 2025, 45(01): 68‒73 https://doi.org/10.1002/cac2.12632

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol. 2010; 8(12): e1000563. CrossRef Google scholar

[2]	Yuan T, Wang Y, Zhao ZJ, Gu H. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. J Biol Chem. 2010; 285(20): 14861-70. CrossRef Google scholar

[3]	Flint AJ, Tiganis T, Barford D, Tonks NK. Development of “substrate-trapping” mutants to identify physiological substrates of protein tyrosine phosphatases. Proc Natl Acad Sci U S A. 1997; 94(5): 1680-5. CrossRef Google scholar

[4]	Zhu JH, Chen R, Yi W, Cantin GT, Fearns C, Yang Y, et al. Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling. Oncogene. 2008; 27(18): 2525-31. CrossRef Google scholar

[5]	Feldinger K, Generali D, Kramer-Marek G. Gijsen M, Ng TB, Wong JH, et al. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget. 2014; 5(16): 6633-46. CrossRef Google scholar

[6]	Cho CY, Koo SH, Wang Y, Callaway S, Hedrick S, Mak PA, et al. Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling. Cell Metab. 2006; 3(5): 367-78. CrossRef Google scholar

[7]	Arshad M, Azad A, Chan PYK, Vigneswara V, Feldinger K, Nafi SNM, et al. Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models. Br J Cancer. 2024; 130(12): 1990-2002. CrossRef Google scholar

[8]	Mohd Nafi SN, Generali D, Kramer-Marek G. Gijsen M, Strina C, Cappelletti M, et al. Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget. 2014; 5(15): 5934-49. CrossRef Google scholar

[9]	Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6(2): 117-27. CrossRef Google scholar

[10]	Joensuu H, Kellokumpu-Lehtinen PL. Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354(8): 809-20. CrossRef Google scholar